PemvidutidevsTesamorelin + Ipamorelin

Pemvidutide (ALT-801) is a once-weekly subcutaneous dual GLP-1 and glucagon receptor agonist, mechanistically similar to mazdutide and survodutide but with a distinct molecular design and a primary development focus on metabolic dysfunction-associated steatohepatitis (MASH) alongside obesity. The dual mechanism combines appetite suppression with enhanced energy expenditure and direct hepatic fat mobilisation.

The GLP-1 receptor component drives the established central appetite suppression through hypothalamic and brainstem signalling, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The glucagon receptor agonism component is what differentiates pemvidutide from pure GLP-1 drugs — glucagon binding in hepatocytes activates adenylyl cyclase and protein kinase A, driving up fatty acid beta-oxidation and ketogenesis while reducing de novo lipogenesis. This directly mobilises stored hepatic triglycerides for energy use rather than continued storage, addressing the core pathology of MASH. In adipose tissue and beyond, glucagon signalling also raises whole-body energy expenditure through thermogenic and futile-cycle mechanisms.

The receptor potency ratio is balanced so that glucagon-driven hepatic glucose output is offset by GLP-1-driven insulinotropic effects, yielding net glycemic improvement alongside enhanced fat oxidation. Phase 2b results in obesity demonstrated approximately 15.6% mean body weight loss at 48 weeks, and parallel MASH trials showed significant reductions in liver fat content alongside improvements in fibrosis markers. Phase 3 trials in both obesity and MASH are now underway, positioning pemvidutide as Altimmune's lead asset and a competitor to mazdutide and survodutide in the dual GLP-1/glucagon class.

The Tesamorelin + Ipamorelin combination pairs the only FDA-approved GHRH analogue with the most selective growth hormone secretagogue, creating a dual-pathway approach similar in principle to CJC-1295/Ipamorelin but with tesamorelin's unique advantages for body composition.

Tesamorelin activates the GHRH receptor on pituitary somatotrophs through the Gs/cAMP/PKA pathway, stimulating GH gene transcription and secretion. Its trans-3-hexenoic acid modification at position 1 provides enhanced receptor affinity and modest DPP-IV resistance compared to native GHRH. Ipamorelin simultaneously activates the GHS-R1a receptor via the Gq/11/PLC/calcium pathway, providing the same synergistic amplification of GH pulses described for the CJC/Ipa combination.

The distinguishing advantage of tesamorelin in this stack is its clinically demonstrated effect on visceral adipose tissue (VAT). In multiple randomized controlled trials for HIV-associated lipodystrophy, tesamorelin reduced trunk fat by 15-18% over 6 months, with visceral fat reduction being proportionally greater than subcutaneous fat reduction. This preferential visceral fat mobilization occurs because visceral adipocytes express the highest density of GH receptors and are most responsive to GH-mediated hormone-sensitive lipase activation. The GH elevations produced by tesamorelin/ipamorelin combination may be greater than tesamorelin alone (due to the synergistic dual-pathway effect), potentially enhancing this visceral fat-targeting effect. The combination also benefits from tesamorelin's full-length GHRH sequence (44 amino acids vs 29 for CJC-1295), which may provide more complete receptor activation, and from the preserved pulsatility that both agents maintain through intact somatostatin feedback regulation.